Terconazole Shortage: What Providers and Prescribers Need to Know in 2026

Patients are increasingly reporting difficulty filling Terconazole prescriptions at local pharmacies. While there is no declared FDA shortage of Terconazole as of 2026, localized stock-outs are creating real challenges for patients — and generating callbacks to your office. This clinical update provides context on the supply situation, guidance on prescribing alternatives, and practical strategies for minimizing patient disruption.

Current Supply Situation

Terconazole (brand: Terazol 3, Terazol 7; generic widely available) is manufactured by multiple generic pharmaceutical companies, including Fougera Pharmaceuticals and others. The FDA has not placed Terconazole on its official Drug Shortages list, indicating no declared manufacturing crisis. However, pharmacy-level stock-outs persist for the following reasons:

Low dispensing volume: Terconazole is a niche prescription vaginal antifungal with significantly lower dispensing frequency than oral antibiotics or common chronic medications. Pharmacies stock it in small quantities.

Three formulation variants: 0.4% vaginal cream (7-day), 0.8% vaginal cream (3-day), and 80 mg vaginal suppository (3-day) are each stocked separately. Not all pharmacies carry all three.

Seasonal demand variation: Vulvovaginal candidiasis has seasonal incidence peaks, particularly in summer, which can temporarily outpace pharmacy inventory replenishment cycles.

Pharmacology Review: When Terconazole Is Specifically Indicated

Terconazole inhibits fungal cytochrome P450 14α-demethylase, blocking conversion of lanosterol to ergosterol and disrupting fungal cell membrane integrity. It is fungicidal against Candida albicans in vitro and also has activity against other Candida species, including non-albicans species that are less responsive to imidazole antifungals.

Clinical scenarios where Terconazole is specifically preferred:

Failed OTC imidazole therapy (miconazole, clotrimazole)

Suspected or confirmed non-albicans Candida infection (C. glabrata, C. tropicalis) where azole activity profile matters

Recurrent VVC requiring prescription-strength topical therapy

Second or third trimester pregnancy where oral fluconazole is preferred to be avoided

Patients with drug interactions or hepatic concerns with systemic fluconazole

Prescribing Alternatives: Clinical Comparison

When Terconazole is unavailable, consider the following evidence-based alternatives:

Fluconazole 150 mg PO single dose: First-line for uncomplicated VVC per CDC guidelines. Generic fluconazole is inexpensive and available at virtually every pharmacy. A 2015 RCT demonstrated comparable clinical cure rates between terconazole suppository and oral fluconazole (81.0% vs. 75.8%, P>0.05) for severe VVC. Avoid in first trimester of pregnancy.

Miconazole (OTC, 3- or 7-day): Reasonable OTC option for uncomplicated VVC in patients where prescription antifungals are not strictly indicated. Clinical cure rates of 80-90% for C. albicans infections.

Clotrimazole (OTC, 3- or 7-day): Effective for uncomplicated VVC; OTC availability makes it easily accessible when prescriptions can't be filled.

Butoconazole (Gynazole-1): Prescription single-dose vaginal cream; effective for uncomplicated VVC. No generic available; may be costly for uninsured patients.

Formulation Switching Within Terconazole

Before switching to a different drug class, consider whether a formulation switch within Terconazole is feasible. All three formulations are indicated for VVC with comparable efficacy:

0.4% cream × 7 nights (20 mg/dose) — if the pharmacy is out of 0.8% cream

80 mg suppository × 3 nights — if cream formulations are unavailable

Note that the suppository base (petroleum-derived triglycerides) can degrade latex/rubber diaphragms and condoms. Counsel patients to avoid latex barrier contraceptives during treatment and for at least 3 days after completing suppository therapy.

39,076+ patients found their medications in stock

39K+

Find Terconazole In Stock Today →

Patient Counseling Points When Terconazole Is Unavailable

Reassure patients that this is not a national shortage and the drug is available elsewhere

Direct them to call large chain pharmacies (CVS, Walgreens, Walmart) or use a medication locating service

Advise that pharmacies can often special-order Terconazole within 24-48 hours

Provide a contingency prescription for an appropriate alternative if needed

How medfinder Can Help Your Patients

medfinder is a paid service that calls pharmacies on behalf of patients to check which ones can fill their specific prescription. Patients enter their medication, dosage, and ZIP code — medfinder contacts pharmacies in their area and texts back the results. This reduces the burden on your office staff from patients calling in to ask which pharmacy has their medication. Learn more about medfinder for providers.

Skip the calls, skip the stress.

Find Terconazole In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Key Clinical Takeaways

No FDA shortage of Terconazole is declared as of 2026; localized stock-outs are a pharmacy inventory issue

Oral fluconazole 150 mg is a well-supported alternative for uncomplicated VVC in non-pregnant patients

Formulation switching within Terconazole (cream to suppository or vice versa) is clinically reasonable

Direct patients to medfinder or suggest they try large chain or mail-order pharmacies before abandoning their Terconazole prescription

Also see: How to Help Your Patients Find Terconazole In Stock: A Provider's Guide.